MAXY FILL® 70cc – 70ml Hyaluronic Acid Body Filler

MAXY FILL® 70cc – 70ml Hyaluronic Acid Body Filler

Product Overview

MAXY FILL® 70cc is a high-volume, cross-linked Hyaluronic Acid (HA) body filler developed for professional soft tissue augmentation, volume restoration and non-surgical body contouring.

Manufactured in South Korea, MAXY FILL® is supplied as a single 70ml sterile vial containing a high-viscosity, cross-linked Hyaluronic Acid gel at a concentration of 20mg/ml.

Unlike conventional facial dermal fillers, MAXY FILL® is formulated for larger-volume applications where soft tissue volume, projection and contour correction may be required.

The cross-linked HA formulation is designed to provide gel cohesiveness, structural support and mouldability while maintaining flexibility within the treated tissues.

Its intended applications include professional body-contouring and soft tissue augmentation procedures, subject to confirmation of the manufacturer's authorised indications, current Instructions for Use and applicable regulatory requirements.

MAXY FILL® 70cc is intended strictly for appropriately qualified medical professionals with advanced training in injectable body-contouring procedures, regional anatomy and complication management.

Pack Contents

Each pack contains:

• 1 × 70ml sterile vial of MAXY FILL® Body Filler

• Cross-linked Hyaluronic Acid gel

• Hyaluronic Acid concentration: 20mg/ml

• Sterile, sealed professional-use packaging

Total Volume: 70ml

The product should remain sealed until immediately before use and must be stored, handled and administered according to the manufacturer's current Instructions for Use.

Product CompositionCross-Linked Hyaluronic Acid – 20mg/ml

MAXY FILL® contains highly purified, cross-linked Hyaluronic Acid at a concentration of 20mg/ml.

Cross-linking creates a stabilised HA gel designed to provide:

• Soft tissue volume

• Structural support

• Gel cohesiveness

• Mouldability

• Resistance to rapid enzymatic degradation

• Progressive biodegradation over time

The supplied product information describes the Hyaluronic Acid as non-animal-derived and produced through bacterial fermentation.

Physiological Buffer Solution

The formulation also contains a physiological buffer solution intended to maintain product stability and support compatibility during professional administration.

The complete formulation, including any cross-linking agents and residual specifications, should be verified against the manufacturer's current technical documentation.

Cross-Linked Hyaluronic Acid Technology

MAXY FILL® utilises cross-linked Hyaluronic Acid technology designed for larger-volume soft tissue augmentation.

Cross-linking creates a three-dimensional gel network that helps improve the structural properties of Hyaluronic Acid compared with non-cross-linked formulations.

The technology is intended to support:

• Improved gel stability

• Increased cohesiveness

• Structural integrity

• Resistance to compression

• Volume retention

• Controlled mouldability

• Slower degradation than non-cross-linked Hyaluronic Acid

The manufacturer describes its production process as being designed to optimise gel purity, viscosity and cohesiveness while reducing manufacturing impurities.

The precise performance characteristics should be assessed using current manufacturer documentation rather than assumed from HA concentration alone.

High-Volume Body Contouring

MAXY FILL® 70cc has been developed for professional procedures requiring larger product volumes than those typically supplied in conventional facial dermal filler syringes.

Its high-viscosity formulation is intended to provide soft tissue support and volume enhancement within anatomically appropriate treatment areas.

Depending on the product's authorised indications and individual patient assessment, potential treatment objectives may include:

• Soft tissue volume restoration

• Improvement in selected body contours

• Correction of suitable contour irregularities

• Improvement in selected asymmetries

• Restoration of volume following tissue loss

• Enhancement of body proportions

The product's suitability for any specific anatomical area must be confirmed against the current manufacturer's Instructions for Use and applicable regulatory requirements.

The supplied product information mentions breast augmentation. However, breast use should not be advertised or undertaken without explicit confirmation of the product's authorised indication, regulatory status and appropriate specialist clinical governance.

Key Benefits

• Professional high-volume body filler

• 70ml sterile presentation

• Cross-linked Hyaluronic Acid formulation

• 20mg/ml HA concentration

• Designed for professional soft tissue augmentation

• High-viscosity gel formulation

• Supports soft tissue volume restoration

• Designed to provide gel cohesiveness

• Supports mouldability and contour correction

• May help improve selected contour irregularities

• May support improvement in soft tissue symmetry

• Provides immediate physical volume following administration

• Cross-linked formulation designed for extended volume retention

• Biodegradable Hyaluronic Acid formulation

• Intended for advanced professional body-contouring procedures

• For appropriately qualified medical professionals only

Individual performance and treatment outcomes depend on the product's verified characteristics, treatment area, patient anatomy and clinical technique.

Potential Treatment Applications

The supplied product information identifies MAXY FILL® 70cc as a body-contouring filler intended for larger anatomical areas.

Potential applications described in that information include:

• Buttock contouring

• Hip contouring

• Hip-dip correction

• Calf contouring

• Selected thigh contour deficiencies

• Suitable soft tissue depressions

• Selected post-liposuction contour irregularities

• Other areas requiring soft tissue volume restoration

These are manufacturer or supplier-described applications, not independently verified authorised indications.

Practitioners must confirm that the specific anatomical area and intended use are permitted by the manufacturer's current Instructions for Use and applicable regulatory requirements before treatment.

Breast augmentation requires separate verification and should not be assumed to be an authorised application.

Treatment suitability must always be established through comprehensive assessment of anatomy, tissue quality, vascular structures, medical history and individual treatment objectives.

Professional Treatment Considerations

MAXY FILL® 70cc should only be administered by appropriately qualified medical professionals with specific training and competence in advanced injectable body-contouring procedures.

Treatment planning should include:

• Comprehensive medical consultation

• Review of medical history

• Assessment of the proposed treatment area

• Evaluation of soft tissue quality

• Assessment of regional anatomy and vascular structures

• Assessment of symmetry and existing contour

• Review of previous cosmetic or surgical procedures

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential complications

• Appropriate documented informed consent

Large-volume body filler procedures require particular attention to regional anatomy, product selection, infection prevention, complication recognition and emergency management.

Product volume, administration technique, injection depth, treatment planes, equipment selection and aftercare must follow the manufacturer's current Instructions for Use and appropriate specialist training.

The suitability of the product for a proposed procedure must not be inferred solely from its 70ml presentation or HA concentration.

Results & Longevity

As a volumising Hyaluronic Acid filler, MAXY FILL® is intended to provide an immediate physical increase in soft tissue volume following appropriate administration.

The final aesthetic appearance may change as initial treatment-related swelling subsides and the tissues settle.

Potential outcomes may include:

• Improved soft tissue volume

• Enhanced body contour

• Improved projection

• Correction of selected contour deficiencies

• Improvement in suitable asymmetries

• Improved overall proportions

The supplied product information reports an approximate longevity of 12–18 months.

This is a manufacturer or distributor-reported estimate and has not been independently verified here. It should not be presented as a guaranteed duration.

Individual longevity may vary according to:

• Treatment area

• Product volume

• Tissue characteristics

• Individual metabolism

• Lifestyle

• Physical activity

• Practitioner technique

• Individual biological response

As the Hyaluronic Acid gradually degrades, the volumising effect is expected to diminish over time.

Any maintenance treatment should be considered only following appropriate professional reassessment.

Storage & Handling

Store MAXY FILL® 70cc according to the manufacturer's current storage recommendations.

To maintain product integrity:

• Keep the product in its original packaging until required.

• Follow the manufacturer's specified storage temperature.

• Protect from inappropriate environmental exposure.

• Inspect the vial and packaging before use.

• Confirm the product's batch number and expiry date.

• Verify product authenticity and traceability.

• Do not use if the sterile packaging is damaged.

• Do not use if the gel appears compromised.

• Do not use after the stated expiry date.

The product should be handled using appropriate aseptic procedures.

Any unused product must be managed according to the manufacturer's Instructions for Use. Do not assume that an opened vial can be stored or reused.

Important Information

MAXY FILL® 70cc is intended strictly for use by appropriately qualified and trained medical professionals.

Advanced injectable body-contouring procedures require specialist knowledge of:

• Regional body anatomy

• Vascular structures

• Soft tissue planes

• Aseptic technique

• Appropriate administration methods

• Patient selection

• Contraindications

• Complication prevention

• Complication recognition and management

• Emergency protocols

Treatment should only proceed following a comprehensive medical assessment, confirmation of product suitability and appropriate informed consent.

Contraindications & Patient Assessment

Treatment suitability must be assessed according to the manufacturer's current Instructions for Use.

Factors requiring particular consideration may include:

• Active infection or inflammation within the proposed treatment area

• Known hypersensitivity to Hyaluronic Acid or another product component

• Pregnancy or breastfeeding

• Relevant autoimmune conditions

• Bleeding disorders

• Impaired wound healing

• Active dermatological conditions

• Previous permanent fillers within the proposed treatment area

• Other medical conditions or contraindications identified during assessment

This list is not exhaustive and does not replace the manufacturer's official contraindications.

Potential Side Effects & Complications

Temporary treatment-related effects may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Localised discomfort

• Itching

• Temporary firmness

• Asymmetry during settling

• Injection-site discomfort

More significant complications associated with injectable body filler procedures may include:

• Infection

• Vascular compromise

• Tissue necrosis

• Delayed inflammatory reactions

• Nodules

• Product migration

• Persistent contour irregularities

• Other complications requiring urgent medical assessment or intervention

Large-volume procedures may present additional risks and require appropriate specialist clinical governance.

Practitioners must be appropriately trained in complication prevention, recognition and management and provide patients with comprehensive written aftercare instructions.

Regulatory & Product Verification

Before purchasing or administering MAXY FILL® 70cc, practitioners should verify:

• Product authenticity

• Manufacturer identity

• Current regulatory status

• Applicable UK market requirements

• Authorised indications

• Current Instructions for Use

• Batch and expiry information

• Product traceability

• Appropriate professional indemnity coverage

The availability of a product for purchase does not itself establish that it is authorised or suitable for every proposed treatment.

Always consult the manufacturer's current Instructions for Use for complete indications, contraindications, precautions, warnings, administration guidance and potential adverse events.

For appropriately qualified professional use only.